Nurix Therapeutics Posts Wider Loss In Q1
(RTTNews) - Nurix Therapeutics, Inc. (NRIX) reported a first quarter net loss of $87.2 million or $0.79 per share compared with a net loss of $56.4 million or $0.67 per share, prior year. Revenue was $6.3 million compared with $18.5 million, a year ago. The company said revenue from the collaboration with Sanofi decreased as the initial research term for certain drug targets ended.
Cash, cash equivalents and marketable securitieswere $540.7 million as of February 28, 2026.
In pre-market trading on NasdaqGM, Nurix shares are down 3.06 percent to $15.85.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.